Nilotinib, an c-Abl/DDR1 inhibitor, reduces pathological markers such as amyloid and tau in the plasma, brain (via positron emission tomography) and cerebrospinal fluid (CSF) of AD patients [9] and may stabilize long-term motor and cognitive decline in PD patients. This evidence concerns the gene MAPT and Alzheimer disease.